Mirum Pharmaceuticals, Inc.

This study is testing whether a new drug called MRM-3379 is safe and can help improve symptoms in males with Fragile X Syndrome. About 60 participants, aged 13 to 45, will take either the drug or a placebo for 12 weeks to see if it makes a difference. The main goal is to check fo…

This global Phase 3 trial is testing whether a new weekly injection called brelovitug (BJT-778) works as well as or better than the current daily injection (bulevirtide) for treating chronic hepatitis D, a serious liver infection. About 172 participants will be randomly assigned …

This study is testing if switching patients from their current hepatitis D medication to a new drug called brelovitug is safe and effective. It will involve about 120 adults who have been on the standard treatment for at least six months. The main goal is to see if the new drug c…

This study is testing whether a new injectable drug called Brelovitug can safely control Hepatitis D infection, a serious liver disease. About 80 people with chronic Hepatitis D will receive either weekly or monthly injections for nearly two years, or start treatment after a 12-w…

This study is testing whether the drug maralixibat is safe and effective at reducing severe, treatment-resistant itching in children and adults with cholestatic liver disease. Participants will be randomly assigned to receive either the study drug or a placebo (inactive substance…

This study follows 100 patients with Alagille Syndrome in Europe who are already taking Livmarli for their liver disease. Researchers want to understand the long-term safety and effectiveness of this medication over time. The study monitors side effects, liver function, and wheth…

This study is testing whether an experimental drug called volixibat can reduce severe itching in people with primary biliary cholangitis (PBC), a chronic liver disease. Researchers will compare volixibat against a placebo in 260 adult participants to see if it safely improves itc…